MedTrace Logo

Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates

NCT00677482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2022-06-01

No results posted yet for this study

Summary

Cytomegalovirus (CMV) is the most common viral infection in patients who have undergone a transplant.Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. The purpose of this study is to assess how the virus interacts with the patient's immune system, so that in the future it may be possible to develop better ways to prevent and treat the virus infection.

Conditions

  • Transplant

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Atul Humar, MD · University of Alberta

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-07-27
Completion
2013-09-23

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677482 on ClinicalTrials.gov